Fighting against viral hepatitis: Lessons from Taiwan

Hepatology

Volumn 54, Issue 2, 2011, Pages 381-392

  Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PEGINTERFERON ALPHA; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CANCER DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MEDICAL RESEARCH; MEDICAL STUDENT; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TAIWAN; VACCINATION; VIRUS HEPATITIS; VIRUS LOAD;

FORECASTING; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; TAIWAN;

EID: 79960721213     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24500     Document Type: Article

References (99)

1. Blumberg BS. Australia antigen and the biology of hepatitis B. Science 1977; 197: 17-25.
2. MacKay P, Pasek M, Magazin M, Kovacic RT, Allet B, Stahl S, et al. Production of immunologically active surface antigens of hepatitis B virus by Escherichia coli. Proc Natl Acad Sci USA 1981; 78: 4510-4514.
3. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347-350.
4. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980; 284: 316-320.
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
6. Sung JL. Occurrence of hepatitis and liver cancer in Taiwan [In Japanese]. J Jpn Assoc Gastroenterol 1973; 70: 977-985.
7. Chen DS. Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: Okuda K, Ishak K, eds. Neoplasms of the Liver. Tokyo: Springer-Verlag; 1987: 71-80.
8. Jerne NK, Nordin AA. Plaque formation in agar by single antibody-producing cells. Science 1963; 140: 405.
9. Chang SS, Hsu SF, Chen DS. Different immunologic behaviors of two strains of mice as revealed by hemolytic plaque technique and methotrexate treatment. J Formosan Med Assoc 1967; 66: 508-516.
10. Sung JL, Wang TH, Yu JY. Clinical study on primary carcinoma of the liver in Taiwan. Am J Dig Dis 1967; 12: 1036-1049.
11. Lin TY. Surgical treatment of primary liver cell carcinoma. In: Okuda K, Peters RL, eds. Hepatocellular Carcinoma. New York: Wiley; 1976: 449-468.
12. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemic sera. JAMA 1965; 191: 541-546.
13. Lander JJ, Giles JP, Purcell RH, Krugman S. Viral hepatitis, type B (MS-2 strain). Detection of antibody after primary infection. N Engl J Med 1971; 285: 303-307.
14. Shih PL, Chang CK, Sung JL. Hepatitis-associated antigen and antibody in Taiwan. J Formosan Med Assoc 1971; 70: 697-706.
15. Sung JL, Sekine T, Lin TM, Nishioka K, Mayumi M, Liaw YF, et al. Hepatitis-associated antigen in hepatocellular carcinoma in Taiwan. J Formosan Med Assoc 1972; 71: 505-508.
16. Tong MJ, Sun SC, Schaeffer BT, Chang NK, Lo KJ, Peters RL. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med 1971; 75: 687-691.
17. Chen DS, Sung JL, Lai MY. A seroepidemiologic survey of hepatitis B virus infection in Taiwan. J Formosan Med Asoc 1978; 77: 908-918.
18. Sung JL, Chen DS. Hepatitis B surface antigen and antibody in liver disease in Taiwan. In: Proceedings of the 5th Asian-Pacific Congress of Gastroenterology; 1976;May 23-27, Singapore.
19. Chen DS, Sung JL. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepato-Gastroenterol 1978; 25: 423-430.
20. Chen DS, Sung JL. Studies on the subtypes of hepatitis B surface antigen-demonstration of vertical and intrafamilial transmission of hepatitis B virus. J Formosan Med Assoc 1978; 77: 263-271.
21. Sung JL, Chen DS. Clustering of different substypes of hepatitis B surface antigen in families of patients with chronic liver disease. Am J Gastroenterol 1978; 69: 559-564.
22. Sung JL, Chen DS. Maternal transmission of hepatitis B surface antigen in patients with hepatocellular carcinoma in Taiwan. Scand J Gastroenterol 1980; 15: 321-324.
23. Sung JL, Chen DS. Geographical distribution of the subtype of hepatitis B surface antigen in Chinese. Gastroenterol Jpn 1977; 12: 58-63.
24. Chen DS, Hoyer BH, Nelson J, Purcell RH, Gerin JL. Detection and properties of hepatitis B viral DNA in liver tissue from patients with hepatocellular carcinoma. Hepatology 1982; 2: 42S-46S.
25. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286: 533-535.
26. Shafritz D, Shouval D, Sherman HI, Hadziyannis S, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 1981; 305: 1067-1073.
27. Lai MY, Chen DS, Chen PJ, Lee SC, Sheu JC, Huang GT, et al. Status of hepatitis B virus DNA in hepatocellular carcinoma. A study based on paired tumor and non-tumor tissues. J Med Virol 1988; 25: 249-258.
28. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989; 96: 527-529.
29. Chen PJ, Chen CR, Sung JL, Chen DS. Identification of a doubly spliced viral transcript joining the separated domains for putative and reverse transcriptase of hepatitis B virus. J Virol 1989; 63: 4165-4171.
30. Chen PJ, Yang PM, Chen CR, Chen DS. Characterization of the transcripts of hepatitis D and B viruses in infected human livers. J Infect Dis 1989; 160: 944-947.
31. Chen PJ, Kuo MYP, Chen ML, Tu SJ, Chiu MN, Wu HL, et al. Continuous expression and replication of the hepatitis delta virus genome in HepG2 hepatoblastoma cells transfected with cloned viral DNA. Proc Natl Acad Sci USA 1990; 87: 5253-5257.
32. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22, 707 men in Taiwan. Lancet 1981; 2: 1129-1133.
33. Chen DS, Sheu JC, Sung JL, Lai MY, Lee CS, Su CT, et al. Small hepatocellular carcinoma-a clinicopathological study in thirteen patients. Gastroenterology 1982; 83: 1109-1119.
34. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its implications. Gastroenterology 1985; 89: 259-266.
35. Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, Yu JY, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56: 660-666.
36. Sheu JC, Huang GT, Chen DS, Sung JL, Yang MY, Wei TC, et al. Small hepatocellular carcinoma: intratumor ethanol treatment using new needle and guidance systems. Radiology 1987; 163: 43-48.
37. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005; 242: 36-42.
38. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study. Intervirology 1978; 10: 196-208.
39. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841.
40. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771-774.
41. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099-1102.
42. Lo KJ, Tsai YT, Lee SD, Yeh CL, Wang JY, Chiang BN, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology 1985; 32: 65-68.
43. Hsu HM. Hepatitis B control and its implementation. In: Hsu HM, ed. Epidemiology of Hepatitis B and Implementation of Immunoprophylaxis in Taiwan [In Han-Chinese]. Taipei, Taiwan: Department of Health, Taiwan; 1989: 95-105.
44. Chen DS, Hsu HM, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen carrier-mothers. JAMA 1987; 257: 2597-2603.
45. Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988; 260: 2231-2235.
46. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Base-line seroepidemiology of hepatitis B virus infection in children in Taipei, 1984. A study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986; 18: 301-307.
47. Tsen YJ, Chang MH, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis B virus infection in children in Taiwan, 1989. Five years after a mass hepatitis B vaccination program. J Med Virol 1991; 34: 96-99.
48. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-908.
49. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796-800.
50. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-1293.
51. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805-816.
52. Chen CY, Hsu HY, Liu CC, Chang MH, Ni YH. Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: a 3-year study of national surveillance of primary school students. Vaccine 2010; 28: 5605-5608.
53. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in Taiwan. J Pediatr 2001; 139: 349-352.
54. Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004; 39: 58-63.
55. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-370.
56. Hsu HC, Wu MZ, Chang MH, Su IJ, Chen DS. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases associated with rapid development of liver cirrhosis. J Hepatol 1987; 5: 260-267.
57. Wu TC, Tong MJ, Hwang B, Lee SD, Hu MM. Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology 1987; 7: 46-48.
58. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-1859.
59. Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005; 11: 7953-7957.
60. Chang MH, You SL, Chen PJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vacinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355.
61. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19-25.
62. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559.
63. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
64. Dienstag JL, Purcell RH, Alter HJ, Feinstone SM, Wong DC, Holland PV. Non-A, non-B post-transfusion hepatitis. Lancet 1977; 1: 560-562.
65. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364.
66. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162: 817-822.
67. Chen PJ, Lin MH, Tai KF, Liu PC, Lin CJ, Chen DS. The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5′ termini of viral genomic and antigenomic RNA. Virology 1992; 188: 102-113.
68. Wang JT, Wang TH, Lin JT, Lee CZ, Sheu JC, Chen DS. Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan. J Gastroenterol Hepatol 1995; 10: 454-458.
69. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon-α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
70. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-1061.
71. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon-α in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
72. Liu CJ, Lai MY, Chao YC, Liao LY, Yang SS, Hsiao TJ, et al. Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43: 742-749.
73. Liu CJ, Chen PJ, Chen DS. A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology 2004; 40: 266.
74. Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opinion Pharmacol 2010; 11: 919-928.
75. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-576.
76. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon α-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
77. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced cirrhosis. N Engl J Med 2004; 351: 1521-1531.
78. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-994.
79. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
80. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-272.
81. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
82. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143.
83. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on non-cirrhotic hepatocellular carcinoma : a case-control study. J Infect Dis 2006; 194: 594-599.
84. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
85. Chen DS, Lai MY, Sung JL. δ Agent infection in patients with chronic liver disease and hepatocellular carcinoma-an infrequent finding in Taiwan. Hepatology 1984; 4: 502-503.
86. Chen PJ, Chen DS, Chen CR, Chen YY, Chen HMH, Lai MY, et al. δ Infection in asymptomatic carriers of hepatitis B surface antigen: low prevalence of activity and effective suppression of hepatitis B virus replication. Hepatology 1988; 8: 1121-1124.
87. Hsu HM, Wang YF, Lo SH, Sun HC, Yip KK, Chen IS, et al. Hepatitis D virus infection among intravenous drug abusers in Taiwan: analysis of risk factors and liver function tests. J Med Virol 1990; 31: 76-81.
88. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis D virus genotypes in intravenous drug users in Taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes. J Clin Microbiol 2002; 40: 3047-3049.
89. Huo TI, Wu JC, Lin RY, Sheng WY, Chang FY, Lee SD. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributing factors. J Gastroenterol Hepatol 1997; 12: 747-751.
90. Chang FL, Chen PJ, Tu SJ, Wang CJ, Chen DS. The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc Natl Acad Sci USA 1991; 88: 8490-8494.
91. Wang CJ, Chen PJ, Wu JC, Patel D, Chen DS. Small-form hepatitis B surface antigen is sufficient in the assembly of hepatitis delta virus-like particles. J Virol 1991; 65: 6630-6636.
92. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990; 247: 1335-1339.
93. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1: 564-569.
94. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505-508.
95. Wang JT, Tsai FC, Lee CZ, Chen PJ, Sheu JC, Wang TH, et al. A prospective study of transfusion-transmitted GB virus C infection: Similar frequency but different clinical presentation compared with hepatitis C virus. Blood 1996; 88: 1881-1886.
96. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antivirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrance Database Syst Rev 2007: CD003510.
97. Chotiyaputta W, Lok AS. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat 2009; 16: 91-93.
98. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
99. Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Miname Y, et al. Clinical characteristics of nonB, nonC-HCC: comparison with HBV and HCV related HCC. Intervirology 2007; 50: 24-31.